Personalized cancer vaccine trial offers new hope for Tough-to-Treat bile duct cancers
NCT ID NCT06564623
Summary
This early-stage study is testing whether a personalized vaccine, made from a patient's own tumor mutations, can boost the immune system to fight advanced bile duct cancer when given with two immunotherapy drugs. The main goals are to check if the combination is safe and if it triggers a strong immune response against the cancer. It is for 25 adults whose cancer has progressed after standard first-line treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SKCCC Johns Hopkins Medical Institution
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.